[Clinical predictors of the therapeutic response to valdoxan in moderate and severe depression]

Authors have analyzed the efficacy of valdoxan in treatment of moderate and severe depression from the position of clinical predictive factors for the most full drug response leading to the remission. A number of patients was 50, duration of therapy was 6 weeks. Due to the recurrent course and a severe depressive episode, the dosage was 50 mg per day from the second week of treatment in most patients (97,5%). Ten patients (20%) were withdrawn from the study. Among patients completed the study, 36 (90%) were considered responders. The most pronounced response leading to the remission was seen in 27 patients. Significantly lower frequency of anxiety depression, night insomnia represented by one of the variants, presence of atypical daily rhythm, as a rule, in the form of worsening in the evening hours, significantly higher frequency of symptoms referred to "Muscle tension" in the structure of generalized anxiety disorder (DSM-IV), persistent or periodic autonomous disorders regardless of the reactive lability or nonsignificant physical tension were specified as clinical predictors for the full response to the drug leading to the remission. Among comorbid disorders, the predictors were paroxysmal anxiety with-or without agoraphobia.